| Baseline characteristics . | n = 129 . |
|---|---|
| Female, n (%) | 32 (24.8) |
| Montreal age, n (%) | |
| A2: 17-40 y | 125 (96.9) |
| A3: >40 y | 4 (3.1) |
| Disease duration, median (IQR), months | 15.7 (5.9-44.7) |
| Montreal location, n (%) | |
| L1: Terminal ileum | 9 (7.0) |
| L2: Colon | 7 (5.4) |
| L3: Terminal ileum and Colon | 113 (87.6) |
| Montreal behavior, n (%) | |
| B1: Inflammatory | 91 (70.5) |
| B2: Stricturing | 20 (15.5) |
| B3: Penetrating | 18 (14.0) |
| Perianal disease, n (%) | 63 (48.8) |
| Active smoking, n (%) | 3 (2.3) |
| Harvey–Bradshaw index, median (IQR) | 6.0 (4.0-9.5) |
| Serum C-reactive protein, median (IQR), mg/L | 18.9 (5.1-33.3) |
| Intestinal ultrasound parameters | |
| Most affected segment, n (%) | |
| Terminal ileum | 74 (57.4) |
| Colon | 55 (42.6) |
| BWT, median (IQR), mm | 6.0 (5.0-7.0) |
| Disruption of BWS (score ≥ 2), n (%) | 99 (76.7) |
| CDS score ≥ 2, n (%) | 107 (82.9) |
| Present of i-fat, n (%) | 74 (57.4) |
| IBUS-SAS, median (IQR) | 72.0 (42.0-85.5) |
| Endoscopic results | |
| Most affected segment, n (%) | |
| Terminal ileum | 65 (50.4) |
| Colorectum | 64 (49.6) |
| Segmental SES-CD, median (IQR) | 6.0 (5.0-8.0) |
| Total SES-CD, median (IQR) | 15.0 (9.5-20.5) |
| Medical history, n (%) | |
| Aminosalicylates | 61 (47.3) |
| Steroids | 42 (32.6) |
| Thiopurines or methotrexate | 36 (28.1) |
| Biologics | 0 (0.0) |
| Concomitant treatments after inclusion, n (%) | |
| Steroid | 12 (9.3) |
| Thiopurines or methotrexate | 47 (36.4) |
| Intensification of infliximab during study, n (%) | 20 (15.5) |
| Baseline characteristics . | n = 129 . |
|---|---|
| Female, n (%) | 32 (24.8) |
| Montreal age, n (%) | |
| A2: 17-40 y | 125 (96.9) |
| A3: >40 y | 4 (3.1) |
| Disease duration, median (IQR), months | 15.7 (5.9-44.7) |
| Montreal location, n (%) | |
| L1: Terminal ileum | 9 (7.0) |
| L2: Colon | 7 (5.4) |
| L3: Terminal ileum and Colon | 113 (87.6) |
| Montreal behavior, n (%) | |
| B1: Inflammatory | 91 (70.5) |
| B2: Stricturing | 20 (15.5) |
| B3: Penetrating | 18 (14.0) |
| Perianal disease, n (%) | 63 (48.8) |
| Active smoking, n (%) | 3 (2.3) |
| Harvey–Bradshaw index, median (IQR) | 6.0 (4.0-9.5) |
| Serum C-reactive protein, median (IQR), mg/L | 18.9 (5.1-33.3) |
| Intestinal ultrasound parameters | |
| Most affected segment, n (%) | |
| Terminal ileum | 74 (57.4) |
| Colon | 55 (42.6) |
| BWT, median (IQR), mm | 6.0 (5.0-7.0) |
| Disruption of BWS (score ≥ 2), n (%) | 99 (76.7) |
| CDS score ≥ 2, n (%) | 107 (82.9) |
| Present of i-fat, n (%) | 74 (57.4) |
| IBUS-SAS, median (IQR) | 72.0 (42.0-85.5) |
| Endoscopic results | |
| Most affected segment, n (%) | |
| Terminal ileum | 65 (50.4) |
| Colorectum | 64 (49.6) |
| Segmental SES-CD, median (IQR) | 6.0 (5.0-8.0) |
| Total SES-CD, median (IQR) | 15.0 (9.5-20.5) |
| Medical history, n (%) | |
| Aminosalicylates | 61 (47.3) |
| Steroids | 42 (32.6) |
| Thiopurines or methotrexate | 36 (28.1) |
| Biologics | 0 (0.0) |
| Concomitant treatments after inclusion, n (%) | |
| Steroid | 12 (9.3) |
| Thiopurines or methotrexate | 47 (36.4) |
| Intensification of infliximab during study, n (%) | 20 (15.5) |
Abbreviations: IQR, interquartile range; BWT, bowel wall thickness; BWS, bowel wall stratification; CDS, color doppler signal; I-fat, inflammatory mesenteric fat; IBUS-SAS, International Bowel Ultrasound Segmental Activity Score; SES-CD, Simple Endoscopic Score for Crohn’s Disease.
| Baseline characteristics . | n = 129 . |
|---|---|
| Female, n (%) | 32 (24.8) |
| Montreal age, n (%) | |
| A2: 17-40 y | 125 (96.9) |
| A3: >40 y | 4 (3.1) |
| Disease duration, median (IQR), months | 15.7 (5.9-44.7) |
| Montreal location, n (%) | |
| L1: Terminal ileum | 9 (7.0) |
| L2: Colon | 7 (5.4) |
| L3: Terminal ileum and Colon | 113 (87.6) |
| Montreal behavior, n (%) | |
| B1: Inflammatory | 91 (70.5) |
| B2: Stricturing | 20 (15.5) |
| B3: Penetrating | 18 (14.0) |
| Perianal disease, n (%) | 63 (48.8) |
| Active smoking, n (%) | 3 (2.3) |
| Harvey–Bradshaw index, median (IQR) | 6.0 (4.0-9.5) |
| Serum C-reactive protein, median (IQR), mg/L | 18.9 (5.1-33.3) |
| Intestinal ultrasound parameters | |
| Most affected segment, n (%) | |
| Terminal ileum | 74 (57.4) |
| Colon | 55 (42.6) |
| BWT, median (IQR), mm | 6.0 (5.0-7.0) |
| Disruption of BWS (score ≥ 2), n (%) | 99 (76.7) |
| CDS score ≥ 2, n (%) | 107 (82.9) |
| Present of i-fat, n (%) | 74 (57.4) |
| IBUS-SAS, median (IQR) | 72.0 (42.0-85.5) |
| Endoscopic results | |
| Most affected segment, n (%) | |
| Terminal ileum | 65 (50.4) |
| Colorectum | 64 (49.6) |
| Segmental SES-CD, median (IQR) | 6.0 (5.0-8.0) |
| Total SES-CD, median (IQR) | 15.0 (9.5-20.5) |
| Medical history, n (%) | |
| Aminosalicylates | 61 (47.3) |
| Steroids | 42 (32.6) |
| Thiopurines or methotrexate | 36 (28.1) |
| Biologics | 0 (0.0) |
| Concomitant treatments after inclusion, n (%) | |
| Steroid | 12 (9.3) |
| Thiopurines or methotrexate | 47 (36.4) |
| Intensification of infliximab during study, n (%) | 20 (15.5) |
| Baseline characteristics . | n = 129 . |
|---|---|
| Female, n (%) | 32 (24.8) |
| Montreal age, n (%) | |
| A2: 17-40 y | 125 (96.9) |
| A3: >40 y | 4 (3.1) |
| Disease duration, median (IQR), months | 15.7 (5.9-44.7) |
| Montreal location, n (%) | |
| L1: Terminal ileum | 9 (7.0) |
| L2: Colon | 7 (5.4) |
| L3: Terminal ileum and Colon | 113 (87.6) |
| Montreal behavior, n (%) | |
| B1: Inflammatory | 91 (70.5) |
| B2: Stricturing | 20 (15.5) |
| B3: Penetrating | 18 (14.0) |
| Perianal disease, n (%) | 63 (48.8) |
| Active smoking, n (%) | 3 (2.3) |
| Harvey–Bradshaw index, median (IQR) | 6.0 (4.0-9.5) |
| Serum C-reactive protein, median (IQR), mg/L | 18.9 (5.1-33.3) |
| Intestinal ultrasound parameters | |
| Most affected segment, n (%) | |
| Terminal ileum | 74 (57.4) |
| Colon | 55 (42.6) |
| BWT, median (IQR), mm | 6.0 (5.0-7.0) |
| Disruption of BWS (score ≥ 2), n (%) | 99 (76.7) |
| CDS score ≥ 2, n (%) | 107 (82.9) |
| Present of i-fat, n (%) | 74 (57.4) |
| IBUS-SAS, median (IQR) | 72.0 (42.0-85.5) |
| Endoscopic results | |
| Most affected segment, n (%) | |
| Terminal ileum | 65 (50.4) |
| Colorectum | 64 (49.6) |
| Segmental SES-CD, median (IQR) | 6.0 (5.0-8.0) |
| Total SES-CD, median (IQR) | 15.0 (9.5-20.5) |
| Medical history, n (%) | |
| Aminosalicylates | 61 (47.3) |
| Steroids | 42 (32.6) |
| Thiopurines or methotrexate | 36 (28.1) |
| Biologics | 0 (0.0) |
| Concomitant treatments after inclusion, n (%) | |
| Steroid | 12 (9.3) |
| Thiopurines or methotrexate | 47 (36.4) |
| Intensification of infliximab during study, n (%) | 20 (15.5) |
Abbreviations: IQR, interquartile range; BWT, bowel wall thickness; BWS, bowel wall stratification; CDS, color doppler signal; I-fat, inflammatory mesenteric fat; IBUS-SAS, International Bowel Ultrasound Segmental Activity Score; SES-CD, Simple Endoscopic Score for Crohn’s Disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
